Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harbour BioMed

www.harbourbiomed.com

Latest From Harbour BioMed

Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round

Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.

Financing Coronavirus COVID-19

HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line

HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.

Ophthalmic Clinical Trials

Indian Firms May Want To Slow March Into China

New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.

Commercial Outlook 2020

Asia Executives On The Move: BMS Names New China GM, New President For Nippon Kayaku

The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.

Appointments China
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Harbour BioMed
  • Senior Management
  • Jingsong Wang, MD, PhD, CEO
    Mai-Jing Liao, PhD, SVP, Head, Bus. Dev.
    Xiaoxiang Chen, MD, EVP, Head, Clin. Dev. & Reg. Science
  • Contact Info
  • Harbour BioMed
    Phone: 21-51370990
    866 Halei Rd., Ste. 311
    Shanghai,
    China
UsernamePublicRestriction

Register